Pembrolizumab: all 1,753 studies that test it

Page 7 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)TerminatedNCT03833167Phase 3Results posted
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03805594Phase 1Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted
• Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of EsophagusCompletedNCT03792347Phase 1Results posted
• Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)CompletedNCT03783078Phase 3Results posted
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results posted
• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)TerminatedNCT03769467Phase 1/2Results posted
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)Active, not recruitingNCT03765918Phase 3Results posted
• An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaCompletedNCT03765229Phase 2Results posted
• Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedNCT03761914Phase 1/2Results posted
• IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)CompletedNCT03753659Phase 2Results posted
• Trial of Pembrolizumab in Cancer of Unknown PrimaryCompletedNCT03752333Phase 2Results posted
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Active, not recruitingNCT03747120Phase 2Results posted
• Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)CompletedNCT03740165Phase 3Results posted
• Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)TerminatedNCT03739138Phase 1Results posted
• NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal CancerActive, not recruitingNCT03734809Phase 2Results posted
• Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerActive, not recruitingNCT03734692Phase 1/2Results posted
• Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeActive, not recruitingNCT03728972Phase 2Results posted
• Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerTerminatedNCT03723915Phase 2Results posted
• Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)CompletedNCT03715205Phase 4Results posted
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Phase 3Results posted
• Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With PembrolizumabTerminatedNCT03709706Phase 1/2Results posted
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk MelanomaActive, not recruitingNCT03698019Phase 2Results posted
• Pembrolizumab in Treating Patients With Stage IB-IV Mycosis FungoidesCompletedNCT03695471Phase 2Results posted
• First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid TumorsTerminatedNCT03681951Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Phase 3Results posted
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
• Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)CompletedNCT03664024Phase 2Results posted
• Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03657641Phase 1/2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03650764Phase 1/2Results posted
• Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaTerminatedNCT03644550Phase 2Results posted
• Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerActive, not recruitingNCT03639948Phase 2Results posted
• Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)CompletedNCT03635567Phase 3Results posted
• Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung StudyCompletedNCT03634241Phase 2Results posted
• A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast CancerTerminatedNCT03632941Phase 2Results posted
• Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)CompletedNCT03631407Phase 2Results posted
• Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaCompletedNCT03630042Phase 2Results posted
• Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCCompletedNCT03625323Phase 2Results posted
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Phase 3Results posted
• Lenvatinib and Pembrolizumab Simultaneous Combination StudyCompletedNCT03609359Phase 2Results posted
• Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian CancerCompletedNCT03602586Phase 2Results posted
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/2Results posted
• Pembrolizumab and EDP1503 in Advanced MelanomaTerminatedNCT03595683Phase 2Results posted
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted
• Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced CancersCompletedNCT03568058Phase 1Results posted
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted
• Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)Active, not recruitingNCT03553836Phase 3Results posted
• Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted
• Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLCCompletedNCT03526887Phase 2Results posted
• A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular CarcinomaCompletedNCT03519997Phase 2Results posted
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results posted
• Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)CompletedNCT03515837Phase 3Results posted
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT03506360Phase 2Results posted
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative DiseasesTerminatedNCT03498612Phase 2Results posted
• Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial CarcinomaTerminatedNCT03486197Phase 2Results posted
• Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerCompletedNCT03475004Phase 2Results posted
• UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeActive, not recruitingNCT03474497Phase 1/2Results posted
• Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)CompletedNCT03473925Phase 2Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior ImmunotherapyTerminatedNCT03463161Phase 2Results posted
• The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical CancerCompletedNCT03444376Phase 1/2Results posted
• Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT03430700Phase 2Results posted
• Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityActive, not recruitingNCT03428802Phase 2Results posted
• Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed GlioblastomaCompletedNCT03426891Phase 1Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)Active, not recruitingNCT03425643Phase 3Results posted
• A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell CancerCompletedNCT03425565Phase 2Results posted
• Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung CancerTerminatedNCT03425006Phase 2Results posted
• A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic ProfileTerminatedNCT03416335Phase 1/2Results posted
• A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03414229Phase 2Results posted
• Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)TerminatedNCT03407170Phase 2Results posted
• Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)Active, not recruitingNCT03405792Phase 2Results posted
• Study of Pembrolizumab Following TACE in Primary Liver CarcinomaCompletedNCT03397654Phase 1/2Results posted
• Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaCompletedNCT03396952Phase 2Results posted
• Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal CancerCompletedNCT03396926Phase 2Results posted
• Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown PrimaryTerminatedNCT03396471Phase 2Results posted
• Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)CompletedNCT03396445Phase 1Results posted
• Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)CompletedNCT03391973Phase 2Results posted
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsActive, not recruitingNCT03390504Phase 3Results posted
• Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical CancerTerminatedNCT03367871Phase 2Results posted
• A Single Dose of Pembrolizumab in HIV-Infected PeopleTerminatedNCT03367754Phase 1Results posted
• Breast Cancer Study of Preoperative Pembrolizumab + RadiationActive, not recruitingNCT03366844Phase 1/2Results posted
• Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)CompletedNCT03364049Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsTerminatedNCT03361228Phase 1/2Results posted
• Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedNCT03358472Phase 3Results posted
• DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedNCT03349450Phase 2Results posted
• Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With GlioblastomaTerminatedNCT03347617Phase 2Results posted
• KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric CancerCompletedNCT03342937Phase 2Results posted
• Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03340766Phase 1Results posted
• Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue SarcomaCompletedNCT03338959Phase 1/2Results posted
• Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal CancersCompletedNCT03332498Phase 1/2Results posted
• Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaCompletedNCT03331341Phase 1/2Results posted
• Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain MetastasesTerminatedNCT03325166Phase 2Results posted
• Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaTerminatedNCT03325101Phase 1/2Results posted
• Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of RecurrenceCompletedNCT03322267Phase 2Results posted
• A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line TherapiesCompletedNCT03321630Phase 2Results posted
• Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyCompletedNCT03319745Phase 2Results posted
• Study of Pembrolizumab and Radiotherapy in Liver CancerTerminatedNCT03316872Phase 2Results posted
• Pembrolizumab in Neoplasms or LymphomasSuspendedNCT03316573Phase 2Results posted

← Pembrolizumab overview